Skip to content
10-K

Annual Report

C4 Therapeutics, Inc. CCCC

0001628280-26-012000

← back to feed
Filed
Feb 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 23, 2026 97.58M sh
Shares Diluted FY 2025 · Dec 31, 2025 82.89M sh
Shares Diluted FY 2025 · Dec 31, 2024 69.37M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $193K
Stock Repurchased FY 2025 · Dec 31, 2024 $194K
Capex FY 2025 · Dec 31, 2025 $607K
Capex FY 2025 · Dec 31, 2024 $180K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$98.69M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$65.16M
Cash And Equivalents FY 2025 · Dec 31, 2025 $74.6M
Cash And Equivalents FY 2025 · Dec 31, 2024 $55.5M
Stockholders Equity FY 2025 · Dec 31, 2025 $256.59M
Stockholders Equity FY 2025 · Dec 31, 2024 $215.99M
Stockholders Equity FY 2025 · Dec 31, 2023 $246.11M
Current Liabilities FY 2025 · Dec 31, 2025 $33.03M
Current Liabilities FY 2025 · Dec 31, 2024 $45.18M
Total Liabilities FY 2025 · Dec 31, 2025 $102.49M
Total Liabilities FY 2025 · Dec 31, 2024 $133.62M
Current Assets FY 2025 · Dec 31, 2025 $258.11M
Current Assets FY 2025 · Dec 31, 2024 $257.77M
Total Assets FY 2025 · Dec 31, 2025 $359.08M
Total Assets FY 2025 · Dec 31, 2024 $349.6M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.27
Eps Diluted FY 2025 · Dec 31, 2024 −$1.52
Eps Basic FY 2025 · Dec 31, 2025 −$1.27
Eps Basic FY 2025 · Dec 31, 2024 −$1.52
Sga Expense FY 2025 · Dec 31, 2025 $36.2M
Sga Expense FY 2025 · Dec 31, 2024 $42.12M
Rd Expense FY 2025 · Dec 31, 2025 $104.24M
Rd Expense FY 2025 · Dec 31, 2024 $110.64M
Net Income FY 2025 · Dec 31, 2025 −$104.99M
Net Income FY 2025 · Dec 31, 2024 −$105.32M
Operating Income FY 2025 · Dec 31, 2025 −$115.22M
Operating Income FY 2025 · Dec 31, 2024 −$119.61M
Revenue FY 2025 · Dec 31, 2025 $35.95M
Revenue FY 2025 · Dec 31, 2024 $35.58M